Atrium Therapeutics Inc NASDAQ NMS - GLOBAL MARKET:RNA
The leadership team, board of directors, and 10% beneficial owners of Atrium Therapeutics Inc, reconstructed from SEC insider filings and proxy statements.
Other Reporting Persons
Other Section-16 reporting persons associated with the issuer.
Gallagher Kathleen P.
—28,861 sharesHoyos Rocio Martin
—16,660 sharesHughes Steven George
—43,097 sharesKenney Stephanie
—5,460 sharesLEVIN ARTHUR A
—131,372 sharesWinslow Brendan R.
—13,601 sharesYounis Husam
—22,657 shares
Recent Form 4 Activity last 90 days
No insider transactions in the last 90 days.
View all insider tradesMethodology
Officers and directors are derived from SEC Forms 3, 4, and 5 filed by reporting persons for this issuer. The roster reflects the most recent disclosed relationship per individual. Officer titles use the issuer-supplied designation from the relationship record.
Independence flags and board committee assignments are sourced from the most recent DEF 14A proxy statement when available. For executive compensation context — base salary, equity grants, performance metrics — refer to the Summary Compensation Table in the issuer's annual proxy.
Cross-references: where a reporting person is matched to a consolidated people profile (same CIK across multiple issuers), the person link routes to the unified profile page so you can see every board seat and officer role in one place.